Stockscreener 앱 받기
0.117
0.09%
0.0001
전일 마감가:
$0.1169
열려 있는:
$0.115
하루 거래량:
624.25K
Relative Volume:
0.38
시가총액:
$1.86M
수익:
-
순이익/손실:
$-66.07M
주가수익비율:
-0.00864
EPS:
-13.5424
순현금흐름:
$-3.11M
1주 성능:
-3.31%
1개월 성능:
-42.28%
6개월 성능:
-94.58%
1년 성능:
+0.00%
1일 변동 폭
$0.1119
$0.12
1주일 범위
$0.1119
$0.138
52주 변동 폭
$0.1119
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
명칭
Propanc Biopharma Inc
전화
61-03-9882-0780
주소
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Compare PPCB vs MOBBW, PSNYW, GOODO, SHMD, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
2.52 | 3.34B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.58 | 423.67M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
19.91 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
6.52 | 362.53M | 52.15M | -21.46M | 0 | -0.4675 |
|
DWLD
Davis Select Worldwide ETF
|
43.90 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc 주식(PPCB)의 최신 뉴스
Propanc Biopharma (PPCB) approves 33M shares and 1:10–1:30 reverse split - Stock Titan
Propanc & Fyonibio Launch Assay for Phase 1b Human Study - The Clinical Trial Vanguard
PPCB Should I Buy - Intellectia AI
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy - Bitget
13% survival in pancreatic cancer; Propanc therapy hits >85% tumor inhibition - Stock Titan
Propanc Biopharma signs contract for Phase 1b cancer trial assay By Investing.com - Investing.com Canada
Propanc Biopharma contracts FyoniBio for drug assay development By Investing.com - Investing.com South Africa
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study - Bitget
Propanc Biopharma contracts FyoniBio for drug assay development - Investing.com
Propanc Biopharma signs contract for Phase 1b cancer trial assay - Investing.com
New cancer trial prep: Propanc and FyoniBio build PRP blood test - Stock Titan
Propanc Biopharma's lead asset PRP shows >85% tumor growth inhibition in preclinical pancreatic models - marketscreener.com
Propanc Biopharma highlights potential of lead asset PRP - TipRanks
Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic Models - TradingView
Deadliest cancer stuck at 13% survival: new PRP therapy targets spread - Stock Titan
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement By Investing.com - Investing.com South Africa
Propanc Biopharma Announces Board Change and New Appointment - TipRanks
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement - Investing.com Nigeria
Propanc Biopharma (PPCB) adds oncology expert Ralf Brandt to board as Kenyon retires - Stock Titan
[EFFECT] Propanc Biopharma, Inc. SEC Filing - Stock Titan
Propanc Biopharma files four new patent applications for cancer treatment By Investing.com - Investing.com South Africa
Propanc Biopharma files four new patent applications for cancer treatment - Investing.com
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results - The Manila Times
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
Certain Warrants of Propanc Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 10-FEB-2026. - marketscreener.com
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market - The Manila Times
Lab tests: Propanc’s PRP slowed tumor growth 85%, human trial planned - Stock Titan
Propanc Biopharma files fourth patent application in two months By Investing.com - Investing.com Australia
Propanc Biopharma files fourth patent application in two months - Investing.com
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations - marketscreener.com
Propanc Biopharma Accelerates IP Momentum: Files Fourth - GlobeNewswire
PPCB Forecast — Price Prediction for 2026. Should I Buy PPCB? - Intellectia AI
Propanc Biopharma files new patent for synthetic cancer treatment - Investing.com
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - The Manila Times
Propanc Biopharma, Inc. Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - marketscreener.com
Propanc Biopharma files new patent for synthetic cancer treatment By Investing.com - Investing.com Canada
Propanc Biopharma advances pancreatic cancer treatment toward clinical trials By Investing.com - Investing.com Nigeria
PPCB (PPCB) Stock Price, News & Analysis - MarketBeat
Propanc Biopharma advances pancreatic cancer treatment toward clinical trials - Investing.com
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer - The Manila Times
Two pancreatic proenzymes could offer new options for deadly cancer - Stock Titan
Propanc Biopharma plans phase 1b trial for cancer treatment PRP By Investing.com - Investing.com Canada
Propanc Biopharma plans phase 1b trial for cancer treatment PRP - Investing.com
Propanc Biopharma Provides Shareholder Update - The Manila Times
Cancer-focused biopharma Propanc plans 2026 human trial, fibrosis work - Stock Titan
Contrasting GRAIL (NASDAQ:GRAL) and Propanc Biopharma (OTCMKTS:PPCB) - Defense World
Propanc Biopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Propanc Biopharma Received Notice of Noncompliance - TradingView — Track All Markets
Propanc Biopharma (NASDAQ: PPCB) details 2M-share Series C resale - Stock Titan
Propanc Biopharma files prospectus for resale of 2 million shares by selling stockholderSEC filing - marketscreener.com
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology - The Globe and Mail
Propanc Biopharma Inc (PPCB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):